Company Overview

Aequus Pharmaceuticals Inc. is a Canada‑based specialty pharmaceutical company that has historically focused on the licensing, commercialization, and lifecycle management of prescription drugs in Canada, primarily in ophthalmology and central nervous system (CNS) therapeutic areas. The company’s business model has centered on acquiring Canadian rights to approved or late‑stage products from larger pharmaceutical partners and commercializing them through a lean, outsourced sales and distribution structure.

Aequus was incorporated in 2013 and is headquartered in Vancouver, British Columbia. Its strategy emphasized targeting niche or underserved patient populations where modest commercial infrastructure could support sustainable revenue. Public disclosures indicate that since 2021–2022, Aequus has significantly reduced or ceased active commercial operations following the divestiture or termination of key product rights. As of the most recent public filings, the company’s ongoing operating status and future commercialization plans are limited, with available public information indicating a shift toward corporate maintenance and strategic alternatives. Data inconclusive based on available public sources regarding current active revenue‑generating products.

Business Operations

Historically, Aequus generated revenue through the commercialization of in‑licensed pharmaceutical products in Canada, primarily via wholesale distribution to pharmacies and hospitals. Its operations were structured around product‑specific licensing agreements, regulatory management, market access, and contracted sales services rather than in‑house manufacturing. The company did not operate production facilities and relied on third‑party manufacturers and distributors.

Key historical assets included Vistitan® (latanoprost ophthalmic solution) for glaucoma, licensed for the Canadian market, along with other ophthalmic and CNS‑related products at various stages of commercialization or development. Public filings indicate that several of these rights were later returned, sold, or terminated, materially reducing operating activity. There is no verified evidence of active international commercial operations outside Canada, and no material subsidiaries or joint ventures have been confirmed in recent disclosures. Data inconclusive based on available public sources regarding current operating segments.

Strategic Position & Investments

Aequus’s strategic positioning was based on acting as a commercialization partner of choice for multinational pharmaceutical companies seeking Canadian market access without building local infrastructure. Growth initiatives historically focused on acquiring additional licensed products, expanding therapeutic focus within ophthalmology and CNS, and leveraging existing commercial capabilities.

Public records show that this strategy was curtailed following the loss or divestiture of key licensed assets, after which the company reported exploring strategic alternatives, including asset monetization and cost containment. No material acquisitions, active portfolio investments, or exposure to emerging technologies such as biologics, gene therapy, or digital health have been conclusively documented in recent filings. Data inconclusive based on available public sources regarding current strategic investments.

Geographic Footprint

Aequus Pharmaceuticals Inc. is headquartered in Vancouver, British Columbia, with historical operations concentrated entirely within Canada. Its commercial activities targeted the Canadian healthcare system, including provincial drug plans, private insurers, hospitals, and retail pharmacies.

The company has not disclosed any material operational presence in the United States, Europe, or other international markets beyond contractual relationships with foreign licensors. There is no verified evidence of international subsidiaries or direct overseas investments as of the latest publicly available information.

Leadership & Governance

Aequus was founded by Doug Janzen, who has played a central role in the company’s strategic direction and public communications. Governance has followed a standard public‑company board and executive structure, with an emphasis on capital discipline and asset optimization in later years.

Key executives disclosed in public filings include:

• Doug Janzen – Chief Executive Officer
• Doug Janzen – Chief Financial Officer (dual role reported in certain periods)
• John McKee – Chair of the Board (historical)
• Grant Thornton LLP – External Auditor (governance oversight role, not an executive)

Public statements from leadership emphasize prudent capital management, maximizing value from existing assets, and evaluating strategic alternatives. Data inconclusive based on available public sources regarding current executive composition beyond the CEO role.